Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDOV-SAFE in Advanced Malignant Solid Tumors
NCT06380309Phase 1Recruiting
- Sponsor
- Peking University
- Start
- May 2024
- Primary completion
- Dec 2025
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of IDOV-Safe in digestive system tumours (6 arms), sponsored by Peking University. Primary endpoints: Dose-Limiting Toxicity up to 2 months, Adverse Events at 1 year and 1 more. Started May 2024; status: recruiting.
02
Drugs
IDOV-Safe
03
Conditions
digestive system tumours
Beyond the preview
Go deeper on NCT06380309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06380309.